Despite distinct etiological and clinical features, most chronic fibrotic disorders have in common a persistent irritant that sustains the production of growth factors, proteolytic enzymes, angiogenic factors, and fibrogenic cytokines (Wilson and Wynn, 2009 ). Together, these factors stimulate the deposition of connective tissue elements that progressively remodel normal tissue architecture. Although initially beneficial, tissue repair pro cesses become pathogenic when they are not regulated, resulting in substantial deposition of extracellular matrix (ECM) components and de velopment of scar tissue. In some diseases, like idio pathic pulmonary fibrosis (IPF), aberrant healing may lead to organ failure and death (Meltzer and Noble, 2008) . Indeed, IPF and other chronic fi brotic lung diseases are associated with high mor bidity and mortality and are generally refractory to existing pharmacological therapy (Shah et al., 2005) . Therefore, better characterization of the molecular and immunological mechanisms of fibrosis is needed to identify new therapeutic modalities for these diseases.
Although a variety of cytokines, chemo kines, and growth factors are important regula tors of fibrosis, we identified a critical role for IL13 in the development of fibrosis in schisto somiasis, a chronic liver disease caused by the par asitic helminth Schistosoma mansoni (Chiaramonte et al., 1999) . Since then, IL13 has been shown to exhibit fibrotic activity in a variety of diseases and tissues, including models of chronic asthma (Blease et al., 2001) , skin fibrosis (Aliprantis et al., 2007) , and bronchiolitis obliterans (Keane et al., 2007) . A few recent studies have also suggested a role for IL13 in bleomycin (BLM)induced pulmonary fibrosis, a wellstudied model of IPF (Jakubzick et al., 2003; FichtnerFeigl et al., 2006) . It has been suggested that IL13 triggers fibrosis by inducing and activating TGF (Lee et al., 2001) . Nevertheless, the mechanism of ac tion of TGF in the development of pulmonary the IL13 decoy receptor (IL13R2) was not significantly involved in the regulation of collagen deposition in the lung (Fig. 1, A and B) . In contrast to S. mansoni egg-induced pul monary fibrosis, BLMinduced fibrosis appeared to be both IL13 and IL13R2 independent. Indeed, C57BL/6 WT, il13 / , and il13R2 / mice all displayed indistinguishable levels of interstitial fibrosis after intratracheal delivery of BLM (Fig. 1, C and D) .
BLM-induced pulmonary fibrosis is characterized by IFN- and IL-17A production
To elucidate the mechanisms involved in acute pulmonary inflammation and fibrosis after BLM administration, we char acterized the immune and pathological responses in mice over a 21d period. Significant weight loss occurred during the first week after intratracheal BLM (Fig. 2 A) . Marked increases in collagen deposition were also seen by day 7, with peak pulmo nary fibrosis developing between days 14 and 21 (Fig. 2 , B, D, and F). Cachexia was associated with significant pneumonia and perivascular and peribronchial inflammation as early as day 4 after BLM and persisting through day 21 (Fig. 2 D) . The peak in fibrosis was preceded by marked increases in matrix metalloproteinase (MMP) 12, tissue inhibitor of MMP (TIMP) 1 (Manoury et al., 2006) , and COL3 messenger RNA (mRNA) expression (Fig. 2 C) , confirming activation of the collagenproducing machinery by BLM. Expression of IFN, IL13, and IL17A was also monitored from restimulated bronchoalveolar lavage (BAL) cells, lung leukocytes, and local draining LN cells (thoracic LN) to determine whether BLM induced fibrosis was associated with a Th1, Th2, and/or Th17 type response. Marked increases in IFN, followed by IL17A, were detected between days 2 and 7 after BLM, whereas sig nificant increases in IL13 were not observed before day 7. In fact, peak IL13 production appeared to occur quite late when compared with IFN and IL17A (Fig. 2 E) . The kinetics of these three mediators suggested that BLMinduced inflamma tory and fibrotic responses are associated with a Th1/Th17 re sponse at early time points and a mixed Th1/Th17/Th2type pattern at later times. As such, they illustrate that BLM triggers significant collagen deposition before the development of the Th2 response (Fig. 2 , B and E), thus contrasting with the S. mansoni egg-induced fibrosis, which is highly dependent on IL4 and IL13 (Chiaramonte et al., 1999) .
IL-10 limits IL-17A/IFN- production and pulmonary fibrosis
Exogenous IL10 treatment suppresses BLMinduced fibrosis (Arai et al., 2000; Kitani et al., 2003; Kradin et al., 2004; Nakagome et al., 2006) ; however, the mechanism of action and role of endogenous IL10 remains much less clear. Using IL10 gfp reporter mice, we identified the major source and pattern of expression of IL10 after BLM challenge. IL10 was detected in CD4 + and CD4  cells; however, the major in crease in IL10 was observed in the CD4 + T cell population with minor increases in CD8 + , CD19 + , and CD11c + cells (unpublished data). The percentage of CD4 + lymphocytes producing IL10 increased within 2 d after administration of fibrosis remains controversial (Kaviratne et al., 2004; Varga and Pasche, 2008) . Although it has been suggested that TGF contributes to BLMinduced inflammation and fibrosis by stimulating fibroblast proliferation and collagenproducing myofibroblasts (Cutroneo et al., 2007) , recent studies also identified a critical role for TGF in the development of IL17A-producing CD4 + T cells (Bettelli et al., 2006; Veldhoen et al., 2006) , which regulate the pathogenesis of a variety of autoimmune and inflammatory diseases (Bettelli et al., 2008) . Similarly, IL1 can stimulate IL17A production (Sutton et al., 2009) , and IL1 is a critical mediator of pulmonary fibrosis (Gasse et al., 2007) . To date, however, a link between IL17A-driven inflammation and pulmonary fibrosis has not been established.
The aim of the current study was to characterize the mechanisms of pulmonary fibrosis and to determine whether IL17A in particular plays an important regulatory role. To do this, three distinct model systems were used, including S. mansoni egginduced pulmonary fibrosis, BLMinduced pulmonary fibrosis, and the recently described IL1-driven fibrosis (Gasse et al., 2007) . We report here that S. mansoni eggmediated fibrosis is IL13 dependent, as il13 / mice developed minimal fibrosis compared with WT mice. In marked contrast, BLMinduced pulmonary fibrosis was inde pendent of IL13 at early time points. Instead, studies with il17a / mice revealed a critical role for IL17A. Using IL10 gfp reporter mice and newly generated IL10 and IL17A double cytokinedeficient animals, we determined that CD4 + cellderived IL10 is required to limit the production and frequency of IL17A + CD4 + and IL17A +  + T cells, thus pre venting the development of severe IL17A-driven fibrosis. We also show that IL17A is essential for the development of fibrosis in response to IL1, thus extending recent studies that described an early innate role for IL1 in pulmonary fibrosis (Gasse et al., 2007) . Together, these studies demon strate that fibrotic tissue remodeling is induced by distinct cytokinedependent mechanisms, with the effector cytokines IL13 and IL17A playing central roles. Moreover, these findings suggest that TGF and proinflammatory mediators like IL1 promote fibrosis by upregulating the production of IL17A, thus identifying IL17A blockade as a potential treatment for fibrotic diseases like IPF.
RESULTS
Fibrosis is mediated by IL-13-dependent and IL-13-independent mechanisms S. mansoni eggs delivered i.v. into S. mansoni egg-sensitized mice induce eosinophilrich pulmonary granulomas around eggs trapped in the pulmonary microvasculature. The lesions are also associated with significant pulmonary fibrosis, as deter mined by hydroxyproline assay of lung tissue (Fig. 1 A) . As ob served in the liver during S. mansoni infection (Chiaramonte et al., 1999) , studies conducted with il13 / mice showed that pulmonary fibrosis is highly dependent on IL13 (Fig. 1 A) . However, unlike chronic liver fibrosis, hydroxyproline assays and Masson's trichrome staining of lung tissue suggested that with pulmonary fibrotic diseases (Uebelhoer et al., 1993) . These observations are also consistent with severe degradation of the basement membrane, enhanced alveolar permeability, and extensive lung injury in IL10-deficient animals.
The exaggerated pathologies observed in il10 / mice were strongly correlated with increased production of IL17A and IFN (Fig. 4 B) . FACS analysis identified IFN-producing TCR + , CD8 + , and CD4 + T cells in BLM challenged mice (Fig. 4 C) , as well as CD3 + TCR + IL17A + and CD3 + CD4 + IL17A + cells in the lungs 7 d after BLM treatment. A 10fold increase in the percentage of CD4 + IL17A + cells was observed in il10 / mice (Fig. 4 C) . In contrast, only a minor increase in the percentage of TCR + IL17A + cells was noted. Nevertheless, a significant increase in the total number of both CD4 + and TCR + populations in the lung (8.5fold increase in CD4 + and 2.5fold increase in TCR + ) were observed in BLMtreatment of il10 / mice, suggesting that IL10 regulates the development and influx of both CD4 + and TCR + populations.
Analyses of whole lung homogenates revealed signifi cantly elevated levels of several IL17A-promoting cytokines in BLM treated il10 / mice. These mediators included IL6, IL12/23p40, the neutrophil chemokine KC (CXCL1), and, perhaps most strikingly, IL1, which was recently impli cated in BLMinduced fibrosis (Gasse et al., 2007) and in amplifying Th17 responses (Sutton et al., 2006 (Sutton et al., , 2009 Fig. 4 D) .
BLM and remained elevated in the BAL and lung at all time points (Fig. 3 A) . CD4 + IL10 + and CD4 + IL10  cells were FACS sorted from the lung of BLMtreated mice and ana lyzed for mRNA transcripts. IL10 gene transcripts were highly upregulated in CD4 + IL10 + sorted cells, confirming faithful reporter activity (Fig. 3 B) . IL17A mRNA tran scripts were also upregulated in CD4 + IL10 + cells, suggest ing coexpression of IL17A and IL10, as previously reported (McGeachy et al., 2007; Stumhofer et al., 2007) and similar to IFN and IL10 coexpressing cells (Anderson et al., 2007; Jankovic et al., 2007; Saraiva et al., 2009) . Neither IFN and Tbet nor TGF and Foxp3 were coexpressed with IL10, suggesting that IL10-producing CD4 cells were not Th1 or Treg cells but, rather, were associated with IL17A-producing cells.
Germ line deletion of the il10 gene significantly acceler ated and increased pulmonary inflammation (Fig. S1 , A and B), with the exacerbated response becoming most obvious by day 7. Histological scores of lung sections also revealed marked increases in perivascular and peribronchial inflammation in BLMtreated il10 / mice, as well as marked increases in pul monary fibrosis (Fig. S1 B) . The increase in pulmonary fibrosis was also verified by quantitative measurements of lung hydroxy proline (Fig. 4 A) . Marked increases in soluble collagen was also detected in the BAL of il10 / mice (Fig. 4 B) , which was consistent with the increased levels observed in patients is consistent with a recent study examining the in vitro dif ferentiation of human Th17 cells (Naundorf et al., 2009) .
Neutrophilia is a common feature of pulmonary fibrosis (Hunninghake et al., 1981; Kinder et al., 2008) , and IL17A has been shown to be critically involved in the recruitment of IL10 may, therefore, operate to regulate the development, in addition to the recruitment, of CD4 + and  + IL17A + cells. In vitro Th17 cell differentiation was not directly influ enced by rIL10 or anti-IL10R treatment (Fig. S2) , indicat ing that IL10 does not directly influence Th17 cells, which ing proinflammatory mediator release and the production of IL17A from CD4 + and TCR + cells.
IL-12/23p40 is required for IL-17A production and pulmonary fibrosis IL12/23p40 promotes the differentiation and expansion of both IL17A and IFN-producing lymphocytes. Given that all of these mediators were elevated in WT mice after BLM treatment, and to a greater extent in il10 / mice, we inves tigated whether IL12/23p40 was regulating the develop ment of IL17A-producing cells and pulmonary fibrosis. neutrophils to sites of inflammation via induction of CXC chemokines (Laan et al., 1999; Witowski et al., 2000; Miyamoto et al., 2003) . Consistent with the marked IL17A response, we detected a significant number of neutrophils in the lungs in BLMtreated mice. Indeed, a substantial increase in neu trophils was observed in both the lung and BAL (not de picted), as well as in the peripheral circulation (Fig. S1 B) . The neutrophil response was also exacerbated in il10 / mice, which was consistent with enhanced IL17A responses (Fig. 4 B) . Collectively, these data indicate that IL10 limits lung injury, neutrophilia, and pulmonary fibrosis by suppress followed a similar pattern (Fig. 5 D) . More importantly, how ever, we show that the exacerbated disease in il10 / mice was highly dependent on IL12/23p40 production because il10 / il12/23p40 / mice were almost completely pro tected from BLMinduced fibrosis (Fig. 5 , B and C). We also extend previous studies by demonstrating mechanistically that deletion of IL12/23p40 is associated with reduced IFN production ( Fig. 5 F) but markedly reduced expression of Using mice deficient in the p40 subunit of IL12/23, we determined that IL12/23p40 is critically involved in orches trating the lung inflammatory response after BLM administra tion (Fig. 5 A) . The reduction in BLMinduced lung damage in p40 / mice was characterized by significantly decreased collagen in the BAL (Fig. 5 B) and lung ( Fig. 5 C) , which is consistent with related studies (Maeyama et al., 2001; Huaux et al., 2002; Sakamoto et al., 2002) . Circulating neutrophilia ciated with decreased IL17A expression (Fig. S3 , B and E) and reduced circulating neutrophils (Fig. S3 A) . Together, these data suggest that IFN may facilitate an IL17A re sponse, as suggested in psoriatic lesions (Kryczek et al., 2008 ). This notion is also supported by an earlier induction of IFN in the lung compared with IL17A (Fig. 2 E) .
IL-17A is required for BLM-induced pulmonary fibrosis
To formally investigate the role of IL17A in BLMinduced pulmonary fibrosis, WT and il17a / mice were challenged with BLM. We also generated il10 / il17a / mice (double KO [dKO]) mice to determine whether the exacerbated lung IL17A (Fig. 5 E) . Our data, however, suggested a particu larly critical role for IL17A because only IL17A was signifi cantly reduced in the double il10 / il12/23p40 / mice (Fig. 5 F) , correlating with markedly reduced disease (Fig. 5,  A and B) . Similar results were obtained by ELISA (Fig. 5 , E and F) and by intracellular cytokine staining (Fig. 5 G) . Nevertheless, previous studies identified an important role for IFN in BLMinduced fibrosis . Conse quently, we revisited this work but investigated whether there was a possible mechanistic link between IFN and IL17A. Interestingly, we discovered that the reduced fi brotic response in ifn / mice (Fig. S3 , C and D) was asso as a dominant and critical mediator in the pathogenesis of BLMinduced pulmonary fibrosis.
IL-1-driven fibrosis is dependent on IL-17A
IL1 mRNA expression (Fig. 6 F) and cytokine production (Fig. 4 D) correlated with the Th17 response and degree of fi brosis after BLM administration. Several recent studies have also identified an important role for IL1 in the development of BLMinduced fibrosis. Indeed, administration of IL1 alone mimics much of the pulmonary pathology caused by BLM (Wang et al., 2000; Gasse et al., 2007; Ortiz et al., 2007; Hoshino et al., 2009) . We confirmed and extended these observations by showing that intratracheal administration of IL1 induces a marked IL17A response (Fig. 7 C) , as well as significant pulmonary fibrosis (Fig. 7, A and B) . The adminis tration of 0.5 µg each of both IL1 and IL17A had a mild additive effect with increased collagen deposition and, most strikingly, increased MMP2 bioactivity (Fig. 7 D) compared with IL1, IL17A, or BLM treatment alone, suggesting in creased turnover of the ECM by IL1 and IL17A.
To test the requirement of IL17A on IL1-induced fi brosis, we administered IL1 to either WT or il17a / mice. As observed earlier, BLMinduced fibrosis was significantly reduced in il17a / mice (Fig. 6) , and, furthermore, IL1-mediated inflammation and fibrosis was also significantly re duced, almost to background levels, in the absence of IL17A (Fig. 7 , E and F). As observed with BLM, intratracheal IL1 induced significant neutrophilia (Fig. 7 G) , TIMP1 in the BAL (Fig. 7 H) , and IFN and IL17A production in the local LNs (Fig. 7 I) . IFN was only slightly elevated in the BAL after IL1 treatment (Fig. 7 I) . These mediators were all reduced in IL1-treated il17a / mice, indicating that IL1-induced pulmonary disease, like BLM, is dependent on IL17A for airway inflammation and pulmonary fibrosis.
IL-17A-dependent pulmonary fibrosis requires TGF-
Many studies have identified a profibrotic role for TGF, particularly in the pathogenesis of pulmonary fibrosis (Cutroneo et al., 2007) . More recently, studies have also suggested important inflammatory activities for TGF, with TGF providing an integral differentiation signal for the develop ment of proinflammatory IL17A-secreting cells (Bettelli et al., 2006; Veldhoen et al., 2006) . We therefore tested whether the profibrotic properties of TGF were linked to IL17A. Intratracheal delivery of BLM or rIL17A induced significant collagen release in the BAL (Fig. 8 A) and deposi tion in the lung (Fig. 8, B and D) . TGF blockade signifi cantly reduced BLM and IL17A-induced fibrosis (Fig. 8 , B and D), identifying a critical requirement for TGF in both BLM and IL17A-induced fibrosis. rIL17A and BLM both increased IL17A responses in the local LNs (Fig. 8 C) , and TGF blockade curtailed endogenous IL17A produc tion, indicating that TGF is required for the genesis of endogenous IL17A. Together, these findings suggest coop erative and amplifying roles TGF and IL17A in the devel opment of fibrosis. fibrosis in IL10-deficient animals was attributed to the en hanced Th17 response. IL17A deficiency significantly reduced BLMinduced fibrosis in WT mice, as shown by analysis of collagen expression in the BAL (Fig. 6 A) and collagen depo sition in the lung (Fig. 6, B and E) . The significant increase in IL17A in il10 / mice (Fig. 4 , B and C; and Fig. 6 H) , which correlated with increased fibrosis, was also reduced to WT levels by deleting IL17A (Fig. 6, A, B , and E). The reduction in fibrosis observed in il17a / mice and il10 / il17a / mice also correlated with a similar decrease in circulating neutrophils (Fig. 6 C) and degree of weight loss (Fig. 6 D) , further illustrating an important role for IL17A in BLMinduced pathology and morbidity. The findings with il10 / il12/23p40 / mice and il10 / il17a / dKO mice also point to IL17A, rather than IFN, as the critical down stream mediator of fibrosis because the il10 / il12/23p40 / mice developed markedly reduced IL17A and fibrotic re sponses yet maintained near normal IFN production. These observations also suggest that IL10 inhibits the development of BLMinduced fibrosis by targeting the proinflammatory IL23-IL17A pathway rather than the IL12-IFN axis.
Il17f, il22, and tnf were elevated in the lungs of BLM treated il10 / mice and remained elevated in il10 / il17a / mice, even though the dKO animals developed much less fi brosis (Fig. 6 F) . Consequently, it seems unlikely that these Th17associated mediators are contributing to the exagger ated fibrotic phenotype in il10 / mice. Interestingly, ifn mRNA (Fig. 6 F) and protein expression (Fig. 6 G) were sig nificantly reduced in il10 / il17a / mice compared with il10 / mice, suggesting that IL17A may facilitate the recruit ment of IFN-producing cells via lymphocyterecruiting chemokines (Zrioual et al., 2008) , cell survival (Sergejeva et al., 2005) , or direct induction of IL12 and IFN by mac rophages (Lin et al., 2009) . It is interesting to note that IL17A and IFN synergistically promote chemokine re sponses in a variety of inflamed tissues (Albanesi et al., 1999; Andoh et al., 2001; Eid et al., 2009) , suggesting a coordinated response between IL17A and IFN.
In contrast to il17f, il22, and tnf, we observed a strong correlation between il1 expression and the degree of fibro sis in il10 / and il10 / il17a / mice. These observations were revealing because IL1 was recently implicated in BLMinduced fibrosis in both humans and mice (Gasse et al., 2007; Ortiz et al., 2007; Hoshino et al., 2009) . il1 expres sion was also significantly reduced in il17a / mice com pared with WT animals, suggesting that either IL17A or IL17A-dependent responses promotes IL1 production. IL1 can indeed promote IL17A responses (Sutton et al., 2009) ; however, whether IL17A directly or indirectly feeds back to enhance IL1 has not been reported. Expression of several ECMassociated genes, including col3, timp1, and mmp12, was also reduced in il17a / mice (Fig. 6 F) . Further more, using zymography we observed reduced MMP2 and MMP9 activity in BAL fluid of il17a / mice compared with WT and in il10 / il17a / mice compared with il10 / mice (Fig. 6 I) . Collectively, these data clearly identify IL17A 
IL-13-dependent pulmonary fibrosis is IL-17A independent
To determine whether IL17A was functioning as a master reg ulator of fibrosis, we also exposed il17a / and il10 / il17a / mice to another model of pulmonary fibrosis. Previous stud ies have shown that S. mansoni egg-induced pulmonary fi brosis is highly dependent on IL13 signaling (Ramalingam et al., 2008) . However, IL17A has been implicated in IL13-associated airway hyperreactivity (Nakae et al., 2002) . The possible connection between IL17A expression and Th2 dependent fibrosis, however, has not been previously inves tigated (Wynn, 2008) . We therefore assessed the impact of IL17A on IL13-dependant pulmonary fibrosis using the S. mansoni egg-induced pulmonary granuloma model. CD4 + IL17A + (1.1%), CD4 + IFN + (13.1%), and CD4 + IL13 + (22.5%) lymphocytes were observed in WT mice 7 d after i.v. delivery of S.mansoni eggs to the lungs (Fig. 4 A) , suggest ing a potential role for IL17A in the development of fibrosis in this model. Deletion of il10 resulted in an approximate doubling of IL17A-producing cells (1.1-2.5%) and a modest increase in IFN-producing cells (13.1-16.3%). Simi larly, when whole lung tissue was analyzed by quantitative RTPCR, significant increases in il17a and ifn mRNAs were observed, with only modest changes in il13 (Fig. S4, A and E). To test the importance of IL17A in this model, WT, il17a / , il10 / , and il10 / il17a / mice were chal lenged i.v. with S. mansoni eggs. In marked contrast to the BLM model (Fig. 6 ), BAL collagen (Fig. S4 B) , hydroxyproline measurements (Fig. S4 C) , and microscopic assessments of lung fibrosis (Fig. S4 , D and G) revealed little to no role for IL17A. Therefore, although IL17A was significantly up regulated and increased further in the absence of IL10 (Fig. S4 , A and E), IL13 appears to function as the dominant profi brotic mediator in this model. Production of IL13 was not significantly affected by the presence or absence of IL17A, suggesting no obvious regulatory role for IL17A (Fig. S4 , E and F). In fact little modulation of the ECMrelated genes (mmp12, timp1, and col6a) was observed in the absence of IL17A (Fig. S4 E) . Moreover, although there was a modest increase in IFN in the IL10-deficient groups, it had no significant impact on the development of IL13-dependent fibrosis, perhaps because IL13 was upregulated 20fold more than IFN. Thus, in marked contrast to the BLM model, where IL17A and, to a lesser extent, IFN appeared to play critical roles in the development of fibrosis, pulmo nary fibrosis induced by schistosome eggs appeared to be de pendent on Th2 cytokines. Thus, unique cytokinedependent mechanisms can be exploited to induce pulmonary fibrosis, with IL17A playing a critical role in BLMinduced fibrosis.
Increased IL-1 and IL-17A in BAL fluid of IPF patients
To determine whether IL1 and IL17A are involved in human IPF, we obtained lung biopsies and BAL fluid from normal volunteers (NVs) and IPF patients. Masson's trichromestained lung sections revealed inflammatory foci within the parenchyma, surrounded by dense collagen deposits (Fig. 9 B) . Similar to the mouse model, IL17A (NV, 1.48 ± 0.98 pg/ml; illustrating the potential utility of targeting IL17A in the treatment of IPF and other fibrotic diseases.
Previous studies have identified important roles for TGF1 and IL13 in the development of fibrosis in a variety of tissues (Chiaramonte et al., 1999; Lee et al., 2001; Varga and Pasche, 2008) , whereas a role for IL17A has remained unclear. Some studies found that IL13 induces and activates TGF1 (Lee et al., 2001) , which then serves as the primary mediator of fi brosis by stimulating collagen synthesis in fibroblasts (Czaja et al., 1989) . Nevertheless, other studies demonstrated that IL13 could function independently of TGF1 (Kaviratne et al., 2004) . To better characterize both the unique and con vergent pathways of fibrosis, we dissected the mechanisms of pulmonary fibrosis in two distinct models in which TGF1 and IL13 have been shown to function as critical mediators. Unexpectedly, although small interfering RNA gene silenc ing studies implicated IL13 in the mechanism of BLM induced pulmonary fibrosis (FichtnerFeigl et al., 2006) , our studies conducted with C57BL/6 il13 / and il13R2 / mice failed to reveal a significant role for IL13 signaling at this early stage of fibrosis in this model. In contrast, S. mansoni IPF, 14.31 ± 3.76 pg/ml) and IL1 (NV, 9.58 ± 1.58 pg/ml; IPF, 21.36 ± 3.97 pg/ml), but not IL22 (NV, 56.1 ± 2.00 pg/ml; IPF, 50.7 ± 1.47 pg/ml; Whittington et al., 2004) , in BAL fluid of IPF patients were increased (Fig. 9 A) , indicting that an IL1-IL17A pathway may be involved in the de velopment of human IPF.
DISCUSSION
We have demonstrated that BLMinduced, but not S. mansoni egg-induced, pulmonary fibrosis is dependent on IL17A produced by  + and CD4 +  + T cells. In addition, we show that IL17A is required for the development of inflammation, neutrophilia, and pulmonary fibrosis after exposure to IL1, a recently described initiator of fibrosis (Wang et al., 2000; Ortiz et al., 2007; Gasse et al., 2007; Cassel et al., 2008; Hoshino et al., 2009) . Mechanistically, using il10 / , il10 / il17a / , and il10 / il12p40 / dKO mice and TGF blockade, we also show that fibrosis is tightly controlled by IL10-producing CD4 + lymphocytes, which regulate IL17A production. Together, these studies identify IL17A as a criti cal mediator of pulmonary fibrosis after BLM administration, position, magnifying the inflammatory cascade. One previous study suggested that IL17A producing  + T cells regulate cellular recruitment with  + T cell-deficient mice develop ing increased inflammation and collagen deposition (Braun et al., 2008) . These data suggest that  + T cells may be het erogeneous and responsible for more than IL17A, with pop ulations of  + T cells providing a brake on the inflammatory response in addition to the early IL17A production. A simi lar scenario could be envisioned for CD4 + T cells, providing both proinflammatory and fibrotic IL17A in addition to antiinflammatory IL10.
Several studies have identified an important regulatory role for IL10 in BLMinduced pulmonary fibrosis (Kradin et al., 2004; Nakagome et al., 2006) . These studies suggested that IL10 controls BLMinduced inflammatory and fibrotic response by regulating chemokine and TGF1 production (Kradin et al., 2004; Nakagome et al., 2006) . However, we also found a marked increase in IL17A in il10 / mice, which develop markedly exacerbated inflammation, neutro phil mobilization, and pulmonary fibrosis after BLM admin istration. These observations are consistent with studies that suggested IL10 could regulate the magnitude and effec tor function of Th17 responses (Fitzgerald et al., 2007; McGeachy et al., 2007; Chang et al., 2008) . Similar to previ ous studies (McGeachy et al., 2007; Stumhofer et al., 2007) , IL10 was often coexpressed with IL17A and RoRt, sug gesting that Th17 cells may develop into IL10-secreting cells to limit Th17 effector function.
To determine whether there was a functional connection between IL10 and IL17A, we generated il10 / il17a / dKO mice and then challenged the animals with BLM. Strik ingly, the increase in BLMinduced pulmonary fibrosis ob served in il10 / mice was completely reversed in the absence of IL17A. As such, these studies explain the severe inflam matory response observed in il10 / mice (Kradin et al., 2004) . They also identify IL17A, which is produced predominantly by CD4 + T cells, as a critical target of IL10. Gene transcripts for the IL17A-related molecules IL17F and IL22 were also increased in the absence of IL10, correlating with exag gerated inflammation and fibrosis (Fig. 6) . However, these molecules were not largely affected in il17a / il10 / mice despite a significant reduction in pulmonary fibrosis, suggest ing that IL17A, but not IL17F or IL22, functions as critical mediators of pulmonary inflammation and fibrosis at this stage. Furthermore, IL22 levels were not significantly different between control and pulmonary fibrosis patients (Whittington et al., 2004) . A comprehensive study by Ishigame et al. (2009) highlighted the overlapping but also distinct roles of IL17A and IL17F. For example, IL17A, but not IL17F, was re quired for DTH, autoimmune encephalomyelitis, and collagen induced arthritis. However, IL17A and IL17F were both required for host defense against Staphylococcus aureus and Citrobacter rodentium. Functionally, IL17F and IL17A also appear to have opposing roles in the allergic lung, with IL17F negatively regulating and IL17A positively regulating Th2 mediated inflammation (Yang et al., 2008) . From our data, it egg-induced pulmonary fibrosis was completely IL13 de pendent. Together, these studies indicate that pulmonary remodeling and fibrosis can be induced by distinct nonover lapping mechanisms, with IL13 functioning as the key driver of S. mansoni egg-driven fibrosis (Kaviratne et al., 2004) and IL17A serving as a key mediator of BLMinduced fibrosis. The discovery that distinct immunological mechanisms can regulate fibrosis suggests that the etiology and/or route of the initial insult, as well as the character of the subsequent inflam matory response, may have a significant bearing on the na ture of the lung wound healing response. The distinct route of tissue damage observed in both models may contribute to the unique fibrotic mechanisms used. Indeed, S. mansoni eggs delivered i.v. primarily disrupt endothelial cells lining the pulmonary vasculature, whereas BLM administered intra tracheally is directly toxic to epithelial cells lining the air way. S. mansoni eggs are also highly immunogenic, inducing robust antigenspecific CD4 + Th2 responses (Everts et al., 2009; Steinfelder et al., 2009) , whereas BLM induces rapid epithelial cell death and destruction of DNA (Hay et al., 1991) , leading to acute proinflammatory Th1/Th17type cytokine production.
Most studies of BLMinduced fibrosis have focused on the hypothesis that TGF regulates the development of pul monary fibrosis by directly promoting the differentiation and activation of collagenproducing myofibroblasts (Varga and Pasche, 2008) . However, recent studies demonstrated that TGF is also critically involved in the development of IL17A-producing lymphocytes (Bettelli et al., 2006; Veldhoen et al., 2006) , which regulate the development of a variety of inflammatory and autoimmune diseases (Tesmer et al., 2008) . Using il17a / mice, we show that IL17A is essential for the development of BLMinduced fibrosis. Similarly, blockade of TGF also significantly reduces BLM and IL17A-induced fibrosis and correlates with reduced IL17A produc tion. These findings suggest that the profibrotic activity of TGF may, at least in part, be attributed to the induction of IL17A. Therefore, by stimulating myofibroblast activa tion and the production of IL17A by T cells, TGF likely promotes BLMinduced fibrosis through both direct and indirect mechanisms. In contrast, development of S. mansoni egg-induced pulmonary fibrosis was completely IL17A independent. Therefore, IL17A appears to induce fibrosis in models where TGF, but not IL13, has been shown to play critical roles. IL17A can directly induce the collagenase MMP1 (Cortez et al., 2007) and progelatinase, MMP3 (Beklen et al., 2007) from various fibroblasts, suggesting that IL17A may facilitate tissue disruption, in addition to its abil ity to promote granulopoiesis (Schwarzenberger et al., 1998) and inflammation. To this end, many studies have identified the proinflammatory properties of IL17A. In the context of inflammation and pulmonary fibrosis, IL17A can stimulate IL6, IL8, and MCP1 from bronchial epithelial cells (Laan et al., 2001) or fibroblasts (Hata et al., 2002; Mahanonda et al., 2008) and, as mentioned in the previous paragraph, is inducible by IL1 and IL23, placing IL17A in a central nificantly fewer neutrophils in the lung than their respective control groups. Finally, IL17A and IL1 were also detected in the BAL fluid of IPF patients. When viewed together, these observations make a compelling case for IL17A in the patho genesis of pulmonary inflammation and fibrosis.
In conclusion, genetic deletion of IL17A significantly at tenuated lung inflammation, neutrophilia, and fibrosis in duced by BLM treatment in both WT and IL10-deficient mice. In contrast, IL17A appeared to play little to no role in the development of IL13-dependent fibrosis. As such, these data identify distinct nonoverlapping immunological roles for IL13 and IL17A in the development of fibrosis. They also suggest that the IL17A pathway might provide a novel ther apeutic target for the treatment of pulmonary fibrosis, for which few therapeutic options currently exist. Kamanaka et al., 2006) . il17a / animals were generated and provided by Regeneron (Leppkes et al., 2009) . il10 / il17a / animals were generated by crossing il10 / with il17a / , with gene expression and protein production confirmed by PCR and ELISA. All animals were housed under specific pathogenfree conditions at the Na tional Institutes of Health in an American Association for the Accreditation of Laboratory Animal Care-approved facility. The NIAID animal care and use committee approved all experimental procedures. A minimum of five mice per group were used in each experiment, unless indicated.
MATERIALS AND METHODS

Animals.
Human tissues. Paraffinembedded lung sections and BAL fluid were ob tained from 14 NVs and 7 patients diagnosed with IPF. 5µm lung sections were stained with Masson's trichrome as described in Histopathology and fi brosis. Subjects were enrolled in protocols 99HG0056 and/or 04HG 0211, which were approved by the National Human Genome Research Institute Institutional Review Board. Written informed consent was ob tained from all subjects. Bronchoscopy with BAL was performed as previ ously described (Ren et al., 2007) .
Reagents and cell culture. For in vitro cell culture, LN cells were iso lated, washed, and plated at 5 × 10 5 cells per well of a 96well plate and stimulated with 1 µg/ml of antiCD3 antibody (clone 2C11; eBioscience). For in vitro Th17 differentiation, OVA peptide 323328 (New England Pep tide) was used at the indicated concentration to differentiate FACSpurified naive CD4 + CD62L hi CD44 lo T cells from OT2 OVA Tg mice into Th17 cells with 20 ng/ml rIL6 (R&D Systems), 5 ng/ml recombinant human TGF (R&D Systems), 10 µg/ml of anti-IL4 (11D11), and 10 µg/ml of anti-IFN (XMG1.1), in combination with irradiated splenocytes or 1 µg/ ml of antiCD3 (eBioscience) and 10 µg/ml of antiCD28 (Invitrogen). rIL10 (R&D Systems) or anti-IL10RAb (BioXell; clone 1B1.3a) were added to cultures at the indicated concentrations. Anti-TGF (BioXell; clone 1D11) was used at 0.5 mg/mouse on days 1, 3, and 5.
Complete blood count (CBC) analysis. EDTAtreated blood was pro cessed for automated counting using a Vista Analyzer (Siemens).
Pulmonary fibrosis models.
For Schistosoma mansoni egg-induced pulmo nary fibrosis, mice were immunized with 5,000 S. mansoni eggs by i.p. injec tion. Tail vein injection of 5,000 eggs was given on day 14, with analysis of fibrotic granuloma development 7 d later on day 21. For BLMinduced pulmonary fibrosis, mice were anaesthetized with a xylazine and ketamine appears that IL17A, and not IL17F or IL22, is the domi nant molecule involved in BLM and IL1-mediated pulmo nary inflammation and fibrosis.
Previous studies identified a role for IFN in BLM induced fibrosis , which was consistent with our findings. Surprisingly, we found that IFN deficiency was associated with reduced IL17A production, suggesting a link between IFN and IL17A. BLM studies performed with il12p40 / and il10 / il12p40 / dKO mice confirmed this association; however, they indicated that IL17A was func tioning as the dominant inducer of fibrosis. Indeed, reduced BLMinduced fibrosis in il12/23p40 / mice was associated with a much greater decrease in IL17A than IFN. A simi lar pattern was observed in BLMtreated il10 / il12p40 / dKO mice. il17a / and il10 / il17a / dKO mice also de veloped relatively normal IFN responses, despite signifi cantly reduced fibrosis. IFN responses in the lungs precede IL17A responses (Fig. 2 E) , suggesting that the IL12-IFN axis may be involved in the recruitment of IL23-dependent IL17A-producing cells into the lung, as previously re ported (Kryczek et al., 2008) . Nevertheless, these findings strongly suggest that the IL23-IL17A axis, rather than the IL12-IFN pathway, plays the dominant role in BLM induced fibrosis, although both mechanisms are clearly in volved and connected.
In addition to TGF1 and IL23 (Langrish et al., 2005) , recent studies identified an important role for IL1 in Th17 responses (Sutton et al., 2006) . Interestingly, a recent study showed that IL1R signaling is involved in BLMinduced pulmonary fibrosis, with exogenous IL1 treatment recapit ulating much of the lung pathology seen with BLM (Gasse et al., 2007) . We confirmed and extended these observations by showing that IL1-mediated inflammation and fibrosis is dependent on IL17A. These findings suggest that IL17A functions as a critical downstream mediator of fibrosis. Inter estingly, the reduced inflammation and fibrosis observed in BLMtreated il17a / animals was associated with reduced IL1 expression, suggesting that IL17A promotes IL1 production, as has been observed in vitro with cultured fibro blasts (Beklen et al., 2007) . These data suggest that IL17A and IL1 crossregulate each other, thus providing an expla nation for their additive roles in BLMinduced fibrosis.
BLMinduced fibrosis is associated with significant neu trophil recruitment to the lung. Indeed neutrophilia is a com mon feature of fibrosis and pulmonary alveolitis in IPF patients (Hunninghake et al., 1981; Kinder et al., 2008) , with airway neutrophilia identified as a predictor of early mortality in IPF (Kinder et al., 2008) . Interestingly, it is now well appreciated that IL17A is involved in the recruitment of neutrophils to sites of inflammation via induction of IL8 and CXC chemo kines, including MIP2 (Laan et al., 1999; Witowski et al., 2000; Miyamoto et al., 2003; Lindén et al., 2005) . Neverthe less, a direct link between IL17A, neutrophilia, and IPF has not been previously investigated. In our study, we observed a strong correlation between IL17A and neutrophil recruit ment, with il17a / and il10 / il17a / mice displaying sig [Ramalingam et al., 2008] ) or designed using Primer Express software (ver sion 2.0; Applied Biosystems; timp1 sense, 5GCAAAGAGCTTTCT CAAAGACC3, and antisense, 5AGGGATAGATAAACAGGGAAA CACT 3; il17a sense, 5TGTGAAGGTCAACCTCAAAGTC3, and antisense, 5AGGGATATCTATCAGGGTCTTCATT3; il17f sense, 5TGCTACTGTTGATGTTGGGAC3, and antisense, 5AATGCC CTGGTTTTGGTTGAA3; il22 sense, 5GTGAGAAGCTAACGTC CATC3, and antisense, 5GTCTACCTCTGGTCTCATGG3; and il1 sense, 5AAGGAGAACCAAGCAACGACAAAA3, and antisense, 5TGGGGAACTCTGCAGACTCAAACT3).
Zymography. 15 µl BAL fluid was mixed with an equal volume of Tris Glycine SDS sample buffer (Invitrogen) and subjected to electrophoresis with 10% gelatin zymogram gels (Invitrogen). According to manufacturer's instructions, the gels were renatured, incubated in a developing buffer for 24 h at 37°C, and stained with Simply Blue Safe Stain (Invitrogen). Pro and active forms of MMP2 and MMP9 were detected using protein molecular weight standards (BioRad Laboratories) and MMP standards (EMD).
Statistical analysis.
Datasets were compared by a Mann Whitney test or oneway analysis of variance, as specified in the figure legends, using Prism software v5. Differences were considered significant (*) at P < 0.05.
Online supplemental material. Fig. S1 demonstrates increased pulmonary inflammation and circulating neutrophilia in BLMtreated il10 / mice, com pared with BLMtreated WT mice. Fig. S2 shows that neither recombinant IL10 nor anti-IL10R blockade has a direct impact on Th17 cell generation in vitro. Fig. S3 corroborates other studies and demonstrates, using ifn / mice, that IFN contributes to BLMinduced pulmonary inflammation and fibrosis. Fig. S4 shows that IL17A is not required for S. mansoni egg-induced pulmonary inflammation and fibrosis. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20092121/DC1. BAL fluid and differential cell counts. Mice were terminally anaesthe tized with sodium pentobarbital. The trachea was cannulated and pulmonary airspaces lavaged with an initial 500 µl of sterile PBS, followed by two 500µl PBS washes. Fluids were centrifuged at 1,200 g, and pellets recovered from all three lavage washes were pooled into 1 ml PBS for total BAL cell counts and cellular analysis. The supernatants of the initial 500 µl BAL fluid were stored at 80°C for biochemical analyses. BAL collagen was measured using a Sircol assay, according to the manufacturer's recommendations.
ELISA. Cytokines, chemokines, and TIMP1 were measured by ELISA using Immulon 2HB plates (Thermo Fisher Scientific) and the manufacturer's guidelines. Paired capture and detection antibodies (R&D Systems) for IL17A (human and mouse), IFN, IL13, IL10, TIMP1, CXCL1 (KC), IL6, IL12/23p40, and IL1 (human and mouse), and CCL17 (TARC) and IL22 (human) were used. Plates were washed with 0.05% Tween 20 in PBS (PBST) and blocked with 5% milk in PBST. Recombinant cytokine stan dards (R&D Systems) were used to assess quantity using a standard curve, with OD acquired at 405 nm in an ELISA reader.
Flow cytometry. After a 3h incubation with 10 µg/ml PMA,1 µg/ml ionomycin, and 10 µg/ml brefeldin A (BFA), cells were stained with anti bodies diluted in PBS with 0.5% BSA (SigmaAldrich) and 0.05% sodium azide (SigmaAldrich) Ma et al., 2008] ), was performed on freshly isolated cells. IL10gfp + cells were detected ex vivo, without stimulation, and were only stained for surface molecules. The expression of surface molecules and intracellular cytokines was analyzed on a flow cytometer (LSR II; BD) using FlowJo software (v.8; Tree Star, Inc.).
Histopathology and fibrosis. Pulmonary collagen was measured as hydroxy proline after hydrolysis of a known weight of lung tissue in 5 ml of 6 N HCl at 110°C for 18 h. The increase in pulmonary hydroxyproline per mouse was calculated based upon total lung weight and expressed as micro moles in the lungs. For histopathological analyses, lungs were inflated with 4% phosphatebuffered formalin and embedded in paraffin for sectioning (HistoPath of America, Inc.). Wright's Giemsa or Masson's trichrome (col lagen, blue; nuclei, dark red; cytoplasm, red/pink) stains were used for analysis of airway inflammation and pathological changes. Perivascular and peribronchial inflammation and collagen evaluations were scored by a blinded observer on an arbitrary 1-4+ basis. The same individual scored all histologi cal features and had no knowledge of the experimental design.
RNA isolation, purification, and quantitative real-time PCR. Total RNA was extracted from lung tissue samples in 1 ml TRIZOL reagent (Invitrogen). The sample was homogenized using a tissue polytron (Omni International), and total RNA was extracted according to the recom mendations of the manufacturer and further purified using the RNeasy Mini kit (QIAGEN). RNA was reverse transcribed using Superscript II Reverse transcription (Invitrogen). Realtime RTPCR was performed on an ABI Prism 7900HT Sequence Detection System (Applied Biosystems). Rela tive quantities of mRNA for several genes was determined using SYBR Green PCR Master Mix (Applied Biosystems) and by the comparative threshold cycle method, as described by the manufacturer, for the ABI Prism 7700/7900HT Sequence Detection System. mRNA levels for each sample were normalized to hypoxanthine guanine phosphoribosyl transfer ase. Primers were either adopted from previously published primer sequences (col6a, mmp12, col3, il13 , ifn [Pesce et al., 2006] , and tnf
